U.S., March 28 -- ClinicalTrials.gov registry received information related to the study (NCT07497438) titled 'Comparison of Two Etoposide Initiation Strategies for Severe Hemophagocytic Lymphohistiocytosis' on March 23.
Brief Summary: Hemophagocytic lymphohistiocytosis (HLH) is an immune-mediated disorder characterized by hyperactivation of the immune system, leading to a cytokine storm responsible for organ failures. Consequently, patients with HLH often require intensive care management, where their short-term prognosis is compromised (1-month mortality: 30 to 40%).
Therapeutic management is urgent and consists in treating associated pathologies and employing immunomodulatory therapy. Currently, there are no clear and consistent recomme...